Acute myeloid leukemia is characterized by arrested differentiation, and agents that overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic acid in acute promyelocytic leukemia. However, the early promise of differentiation therapy did not translate into clinical benefit for other subtypes of acute myeloid leukemia, in which cytotoxic chemotherapeutic regimens remained the standard of care. Recent advances, including insights from sequencing of acute myeloid leukemia genomes, have led to the development of targeted therapies, comprising agents that induce differentiation of leukemic cells in preclinical models and clinical trials, thus rejuvenating interest in differentiation therapy. These agents act on various cellular processes including dysregulated metabolic programs, signaling pathways, epigenetic machinery and the cell cycle. In particular, inhibitors of mutant IDH1/2 and FLT3 have shown clinical benefit, leading to approval by regulatory bodies of their use. Besides the focus on recently approved differentiation therapies, this review also provides an overview of differentiation- inducing agents being tested in clinical trials or investigated in preclinical research. Combinatorial strategies are currently being tested for several agents (inhibitors of KDM1A, DOT1L, BET proteins, histone deacetylases), which were not effective in clinical studies as single agents, despite encouraging anti-leukemic activity observed in preclinical models. Overall, recently approved drugs and new investigational agents being developed highlight the merits of differentiation therapy; and ongoing studies promise further advances in the treatment of acute myeloid leukemia in the near future.
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by impaired differentiation and uncontrolled clonal expansion of myeloid precursors. A varied range of genetic and epigenetic alterations disrupt normal differentiation of myeloid precursors leading to maturation arrest coupled with self-renewal capacity. Despite extensive research and remarkable advances in our understanding of the molecular mechanisms governing AML pathogenesis, chemotherapy-based treatment regimens developed in the 1970s constitute the standard of care.1 All-trans retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is a notable exception, which not only revolutionized the clinical outcome of APL, but also demonstrated that inducing terminal differentiation is an effective mode of treating AML.2 This therapeutic approach of using pharmacological agents to stimulate differentiation of immature cancer cells into more mature forms is termed differentiation therapy. Apart from its overt effect on APL blasts, ATRA also differentiated some AML cell lines lacking PML-RARA and the drug showed some activity in a few clinical trials;3-6 however, in general, ATRA has been ineffective in non-APL subtypes of AML.7-13 Initial studies with the HL-60 cell line also suggested that many compounds could induce terminal differentiation, including cytokines, vitamin D3 analogs and ligands of PPAR.14 However, their therapeutic utility has been limited.15, 16
More recently, novel oncogenic pathways in AML have been identified, facilitating the development of targeted therapies, and heralding a new era in AML treatment. New differentiation-inducing agents that target mutant isocitrate dehydrogenase (IDH)1, IDH2 or FLT3 have gained regulatory approval. Other agents directed against distinct targets are being developed to induce differentiation of leukemic blasts. This review updates our previous description of AML differentiation therapy,14,15 with a focus on new developments in the field, especially in the last decade.
Newly-approved targeted therapies for acute myeloid leukemia
Agents targeting two distinct oncogenic events, IDH1/2 mutations and activating FLT3 mutations, have been approved for AML therapy since 2017. These agents exert anti-leukemic activity by inducing differentiation of leukemic blasts and are exciting additions to differentiation therapy of AML.
Targeting mutant IDH1/2 enzymatic activity induces differentiation
IDH1 and IDH2 are NADP+-dependent enzymes that normally catalyze the oxidative decarboxylation of isocitrate to produce -ketoglutarate in the tricarboxylic acid cycle.17 Somatic mutations in the active site of IDH1 and IDH2 are observed in about 20% cases of AML and 5% of myelodysplastic syndromes.17 Mutations of IDH1 and IDH2, which largely occur in a mutually exclusive manner, result in accumulation of the oncometabolite D-2- hydroxy glutatrate (2-HG).18 2-HG disrupts activity of - ketoglutarate-dependent enzymes including members of the ten-eleven-translocation (TET) family of 5-methylcytosine hydroxylases and the jumonji-domain-containing group of histone lysine demethylases. This leads to a block of normal differentiation and promotes oncogenic transformation. 19-21
Ivosidenib (AG-120; Tibsovo, Agios) is a first-in-class inhibitor of mutant IDH1 developed from the prototype compound AGI-5198.22 Ivosidenib is effective against AML cells harboring mutant IDH1 by lowering their 2-HG levels and causing cellular differentiation.22 A phase I dose escalation and expansion study of this drug in patients with relapsed/refractory AML harboring IDH1 mutations resulted in about 30% of cases achieving either complete remission (CR) or CR with partial hematologic recovery (CRh), with a median overall survival (OS) of 9 months (NCT02074839) (Table 1).23 Ivosidenib induced myeloid differentiation of AML blasts, and differentiation syndrome (DS) occurred in about 11% of patients23 (see description of ‘Differentiation syndrome’ below). A subset of patients, who achieved clearance of mutant IDH1, showed longer CR (11.1 vs. 6.5 months) and OS (14.5 vs. 10.2 months) compared with those without clearance of the mutant IDH1. Notably, patients who did not respond to ivosidenib had significantly higher rates of mutations of the receptor tyrosine kinase pathway.23 In a recent study, ivosidenib monotherapy was shown to induce durable remissions in patients with newly diagnosed IDH1-mutant AML ineligible for standard chemotherapy.24 Preliminary results from an ongoing phase Ib/II trial (NCT02677922) showed that the combination of ivosidenib with 5-azacytidine was well tolerated with CR and overall response rates exceeding those achieved with 5-azacytidine alone.25 In 2018, the Food and Drug Administration (FDA) approved the use of ivosidenib for patients with IDH1- mutant relapsed/refractory AML; and subsequently the FDA approval was granted for newly diagnosed IDH1- mutant patients who are ≥75 years old or who have comorbidities precluding the use of intensive induction chemotherapy. Other inhibitors of mutant IDH1, which were effective in preclinical models include AG-881 (Agios Pharmaceuticals), IDH-305 (Novartis Pharmaceuticals), FT2102 (Forma Therapeutics) and BAY1436032 (Bayer); however, only FT2102 is being developed further for hematologic cancers (Table 1).26
The first selective inhibitor of mutant IDH2 was AGI- 6780, which potently inhibited its aberrant enzyme activity in AML cells and induced differentiation of these cells in vitro.27 Subsequently, a clinically useful inhibitor, enasidenib (AG-221; IDHIFA), was developed by Agios Pharmaceuticals/Celgene Corporation. This drug reduced 2-HG levels and induced differentiation of IDH2-mutant AML blasts ex vivo and in xenograft mouse models, conferring these mice with a survival advantage.28 In a phase I/II study of relapsed/refractory AML with IDH2 mutation (either R140 or R172), the drug was well-tolerated and induced hematologic responses associated with maturation in 40% of patients, half of whom achieved CR (NCT01915498).29 The median OS among patients with relapsed/refractory AML was 9.3 months, while it was 19.7 months in those who attained CR with enasidenib.29 Moreover, older patients who were not candidates for standard cytotoxic therapy had a 30% response rate to enasidenib, including an 18% CR rate.30 The differentiated neutrophils retained the IDH2 mutation, supporting differentiation as the mechanism of action of enasidenib.31,32
While enasidenib potently suppressed 2-HG in most patients, levels of 2-HG were not predictive of clinical response. Lack of clinical response despite suppression of 2-HG levels suggests the need for additional biomarkers of drug response. An absence of response to enasidenib could also occur because of other genetic or epigenetic abnormalities in the leukemic clones. For example, co-occurring mutations of genes in the RAS pathway are significantly associated with the lack of response to enasidenib.32 In 2017, enasidenib received FDA approval for use in adult relapsed/refractory AML patients with IDH2 mutations. Ongoing clinical studies are evaluating the efficacy of combining mutant IDH1/2 inhibitors with either 5-azacytidine or other therapeutic agents (Table 1). Interestingly, an interim analysis of an ongoing study (NCT02677922) showed significantly higher response and CR rates with a combination of enasidenib and 5-azacytidine than with 5-azacytidine monotherapy in patients with newly diagnosed AML, who were not candidates for intensive chemotherapy.33 Encouraging response rates noted in a preliminary analysis of an ongoing trial also support the feasibility of combining either ivosidenib or enasidenib with standard AML induction therapy in frontline treatment of the newly diagnosed patients harboring mutations of IDH1 and IDH2, respectively. 34
Despite the clinical benefit of selective inhibitors of mutant IDH1/2, acquired resistance to this targeted therapy poses new challenges in treating AML. For instance, IDH2-mutant patients developed resistance to enasidenib by acquisition of a second mutation at residues located at the interface where enasidenib binds to the IDH2 dimer.35 Resistance to enasidenib can also occur through acquisition of additional oncogenic mutations in other genes.36 Similarly, secondary resistance to ivosidenib was associated with acquisition of either IDH1-second site mutations or mutations of IDH2 or RTK pathway genes.37
Differentiation syndrome following mutant IDH1/2 therapy
DS, originally described as retinoic acid syndrome, is a common side effect observed in APL patients treated with ATRA or arsenic trioxide. It is a serious complication that develops within 1-3 weeks of initiation of differentiation therapy in APL.38 The pathogenesis of DS involves release of pro-inflammatory cytokines from differentiating blast cells, leading to a systemic inflammatory state. This, combined with increased vascular permeability, leads to a myriad of clinical symptoms that include unexplained fevers, weight gain, hypotension, rash, hypoxia, renal failure, dyspnea with pulmonary infiltrates and pleuropericardial effusion.38 Although potentially life-threatening, clinical symptoms of DS are routinely managed using corticosteroids, while discontinuation of differentiation therapy might be required in cases with severe DS.38,39
DS, similar to that observed in APL following ATRA/arsenic trioxide therapy, has also been reported in patients treated with inhibitors of mutant IDH1/2. The most common clinical features of IDH-DS were dyspnea and pulmonary infiltrates or pleuropericardial effusion, while hypotension was the least common symptom.40 IDH-DS was effectively managed by dose interruption and treatment with glucocorticoids and hydroxyurea.23,29,41 In contrast to a rapid occurrence of DS in APL (median of 12 days),38,42,43 the onset of DS was delayed in patients treated with IDH inhibitors.23,40,41 A recent comprehensive analysis concluded that the incidence of DS in IDH inhibitor-treated patients (19%)40 is similar to the rate observed for ATRA-treated APL (∼25%).39,42,43 This necessitates routine monitoring for DS in patients on IDH inhibitor therapy.
Further mechanistic studies are necessary to establish how inhibition of mutant IDH1 and IDH2 relieves the block in myeloid differentiation. Inhibitors of mutant IDH1/2 potently suppress 2-HG, and this is likely to restore the activity of -ketoglutarate-dependent enzymes that regulate DNA and histone methylation. Therefore, studies need to focus on investigating the function of TET enzymes and jumonji histone lysine demethylases, and whether restoration of their function correlates with clinical outcome in subjects treated with inhibitors of mutant IDH1/2. A better understanding is also required of why the clinical response to IDH inhibitors is variable despite robust inhibition of 2-HG levels. In addition, better predictive biomarkers are needed to enhance the therapeutic utility of IDH inhibitors.
FLT3 inhibitors promote differentiation of acute myeloid leukemia blasts
FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML (~30%), with two distinct alterations, either an internal tandem duplication (FLT3- ITD) in the juxtamembrane domain or point mutations in the tyrosine kinase domain (TKD). These activating mutations lead to ligand-independent, constitutive FLT3 signaling which promotes proliferation of leukemic cells. Activation of FLT3 also suppresses myeloid differentiation by inhibiting the function of CEBPA via ERK1/2-mediated phosphorylation, while pharmacological inhibition of FLT3 causes granulocytic differentiation of AML cells.44
Early studies with FLT3 inhibitors demonstrated clinical manifestation of differentiation with evidence of neutrophilic dermatoses.45-47 Since then, several inhibitors of FLT3 have been investigated in clinical trials and two agents, gilteritinib and midostaurin, have received regulatory approval. In clinical studies, the differentiation-inducing effect of FLT3 inhibition is clearly evident with selective FLT3 inhibitors, gilteritinib and quizartinib.
Gilteritinib (Xospata, Astellas Pharma) is a type I FLT3 inhibitor active against both ITD and TKD mutations. In a murine xenograft model, gilteritinib induced regression of tumors expressing mutant FLT3.48 In an initial clinical study, 49% of FLT3-mutant AML patients responded to gilteritinib. Of note, 37% of the patients who had received prior treatment with another FLT3 inhibitor responded to gilteritinib [NCT02014558 (CHRYSALIS study)] (Table 2).49 Significantly, gilteritinib stimulated differentiation towards granulocytic and monocytic lineages in about half of the FLT3-mutant patients, who exhibited significant reduction in marrow blast percentage, even though the mutation burden of FLT3 was unchanged.50 In this subgroup of patients, DS was reported in two patients, in whom it was resolved with glucocorticoid therapy.50 Intriguingly, the authors noted no apparent signs of myeloid differentiation in the other half of patients treated with gilteritinib although reductions in AML blasts and bone marrow cellularity were observed. This alternate pattern of response to gilteritinib was associated with a reduction in allele frequency of mutant FLT3 and indicated that mechanisms other than induction of myeloid differentiation, might contribute to the anti-leukemic effect of gilteritinib. Promising data emerging from an interim analysis of a phase III clinical study (NCT02421939 [ADMIRAL study]) comparing gilteritinib monotherapy to salvage chemotherapy in FLT3-mutant relapsed/refractory AML patients led to the FDA (November 2018) and European Medicines Agency (EMA) (September 2019) approving single-agent gilteritinib therapy in adult patients with FLT3-mutated relapsed/refractory AML. This trial demonstrated significantly longer OS (9.3 months vs. 5.6 months) and higher response rates (CR/CRh rates of 34% vs. 15%) in gilteritinib- treated patients than in those treated with chemotherapy.51 The efficacy of gilteritinib is also being explored in a variety of other clinical settings, including in combination with either 5-azacytidine or other chemotherapeutic agents, as well as for maintenance therapy in patients with FLT3-mutated AML (Table 2).
Quizartinib is a type II inhibitor that binds adjacent to the ATP-binding domain when the FLT3 protein is in its inactive conformation and, therefore, lacks activity against TKD-mutant FLT3.52 It is a highly potent and selective inhibitor of FLT3 and showed comparatively greater efficacy as a single agent than chemotherapy in a larger phase III trial (QuANTUM-R study; NCT02039726). In this study of relapsed/refractory AML with FLT3-ITD, quizartinib monotherapy prolonged OS compared with salvage chemotherapy.53 Quizartinib caused terminal myeloid differentiation of leukemic blasts with a surge in the number of FLT3-ITD-retaining neutrophils, and development of clinical DS.54 Superior response rates were obtained in relapsed/refractory AML harboring FLT3-ITD when quizartinib was combined with either 5-azacytidine or low-dose cytarabine.55 A larger, placebo-controlled trial (QuANTUM-First; NCT02668653) combining quizartinib with standard induction and consolidation chemotherapy in newly-diagnosed FLT3-ITD-positive AML patients is ongoing (Table 2).
Although gilteritinib and quizartinib act as differentiating agents, differentiation is not universally observed in all patients treated with FLT3 inhibitors, suggesting alternative mechanisms of clearing AML blasts. Midostaurin (Rydapt, Novartis) is a first-generation FLT3 inhibitor that received FDA and EMA approval in 2017 for use in adults with FLT3-mutated newly diagnosed AML when combined with intensive chemotherapy; the EMA also approved midostaurin for single-agent maintenance therapy. As a single-agent, midostaurin causes a reduction in leukemic blasts in FLT3-mutant relapsed/refractory AML patients, without achieving CR.56 Combining midostaurin with chemotherapy significantly improved its efficacy, with a 92% CR rate being observed in FLT3-mutated patients (Table 2).57 Moreover, in a large, phase III, double-blind, placebo-controlled trial in newly diagnosed FLT3- mutated AML, addition of midostaurin to chemotherapy resulted in significant improvements in OS and event-free survival.58 However, none of these studies demonstrated that midostaurin exerted its anti-leukemic activity via differentiation of AML blasts. Midostaurin is a broad-range multikinase inhibitor, which targets KIT, PDGFR/, VEGFR2, and members of the serine/threonine kinase PKC family, apart from inhibiting FLT3. Thus, it is possible that its clinical efficacy results from blocking additional pro-survival and proliferation signals. Indeed, midostaurin also caused clinical responses in FLT3-negative AML and further trials are carefully investigating its clinical activity in FLT3wild-type AML (Table 2). Crenolanib is another selective FLT3 inhibitor, which produced high response rates in newly-diagnosed and relapsed FLT3-mutant AML patients, as well as those refractory to other tyrosine kinase inhibitors.52,59 It is being investigated in several late-stage clinical studies, primarily in combination with chemotherapy (Table 2). Several preclinical studies have demonstrated that FLT3 inhibitors broadly induce apoptosis of AML cells.60,61 Hence, FLT3 inhibitors possibly function through multiple pathways, among which induction of apoptotic cell death and terminal differentiation of leukemic blasts are prominent.
Secondary resistance frequently develops in AML patients treated with FLT3 inhibitors, and complex patterns of clonal selection and evolution have been reported.52,59,62-64 Acquired resistance to type II FLT3 inhibitors often involves gain of secondary mutations either in the TKD or the gatekeeper residues of the FLT3 gene,65 and type I inhibitors, such as gilteritinib and crenolanib, which have activity against both ITD and TKD mutations are effective in these patients. Overall, rational combination therapies with agents targeting known resistance pathways are needed to eradicate leukemic clones.
Other differentiation-inducing agents evaluated in clinical trials
The approval of new targeted drugs bodes well for AML differentiation therapy, but improving therapeutic options for all subgroups remains a major challenge. Epigenetic enzymes are attractive targets for AML therapy and inhibitors of histone deacetylases (HDAC), KDM1A, DOT1L and BET proteins have been extensively studied in AML. We discuss below several of these drugs, which stimulated differentiation of leukemic blasts in preclinical models, but their single-agent activity in clinical trials has been disappointing.
Inhibition of KDM1A (LSD1) promotes myeloid differentiation
KDM1A is a demethylase enzyme with specificity for monomethyl- and dimethyl-histone H3 lysine-4 (H3K4) and lysine-9 (H3K9). It is highly expressed in AML cells and is required to maintain the oncogenic program downstream of MLL-AF9.66 Pharmacological inhibition of this enzyme potentiates ATRA-induced differentiation of AML cells and diminishes their engraftment in immune-deficient mice.67 Combined treatment with ATRA and tranylcypromine (an inhibitor of KDM1A) caused a gene-specific increase in H3K4me2 levels and upregulation of myeloiddifferentiation associated gene expression.67 MLL-AF9- expressing cells treated with KDM1A inhibitors also exhibit gain in chromatin accessibility at sites bound by PU.1 and CEBPA; and depletion of either of these transcription factors confers resistance of MLL-AF9-expressing cells to KDM1A inhibition.68 Preclinical results have also demonstrated sensitivity of other AML subtypes (e.g., AML with RUNX1-RUNX1T1) to KDM1A inhibitors.69 The efficacy of tranylcypromine combined with ATRA is being evaluated in clinical trials (Table 3).
ORY-1001 (Iadademstat), a more potent and selective derivative of tranylcypromine, effectively reduced growth of AML cell lines, induced expression of differentiation markers and increased survival of murine xenograft models. 70 The drug is synergistic with ATRA as well as with other epigenetic inhibitors targeting DOT1L, DNMT1 or HDAC.70 Because of favorable pharmacological characteristics and tolerability in a phase I/IIa study in relapsed/refractory AML,71 ORY-1001 is now being investigated in combination with 5-azacytidine in elderly AML individuals who are not eligible for intensive chemotherapy (Table 3). Other KDM1A inhibitors are currently being investigated as either monotherapy or in combination with ATRA in early phase clinical trials (Table 3).
DOT1L inhibition in MLL-rearranged acute myeloid leukemia
Rearrangements of the MLL gene occur in 5-10% of AML cases and are associated with an adverse prognosis. DOT1L, a H3K79 histone methyltransferase, is recruited by MLL-fusion proteins resulting in increased H3K79 methylation at target gene loci.72,73 This mis-targeting of DOT1L activity is essential for the transforming ability of MLL fusion proteins, and enhances expression of HOXA9 and MEIS1.74-76 Depletion of DOT1L in MLL-AF9 leukemic cells induces differentiation and apoptosis.75
EPZ004777 was the first selective inhibitor of DOT1L, which inhibited H3K79 methylation and reversed the gene expression signature of MLL fusion leukemias, including downregulation of HOXA cluster genes.74,75,77 This drug stimulated myeloid differentiation in murine and human cells harboring MLL fusions.76-78 Pinometostat (EPZ-5676) is closely related to EPZ004777 but is more potent and has better pharmacokinetic properties.79 However, in a phase I trial of pinometostat in advanced stage MLL-rearranged leukemia, only two of 51 patients achieved a CR, while seven non-responding patients also exhibited morphological changes consistent with myeloid differentiation (NCT01684150).80 Despite apparent biological activity (inhibition of H3K79 methylation) in patients, pinometostat as a stand-alone therapy was not sufficient to produce a clinical benefit. This lack of therapeutic activity may be attributed to heterogeneity of MLL fusion proteins, which might result in differential sensitivity to DOT1L inhibitors.
Given their insufficient clinical efficacy as single agents, combinatorial strategies incorporating DOT1L inhibitors are being tested. Preclinical studies have shown synergistic anti-leukemic effects of combining DOT1L inhibition with either cytotoxic chemotherapy, hypomethylating agents, or inhibition of KDM1A or menin (a MLL cofactor), 81-84 suggesting that dual targeting of the MLL-fusion complex may prove superior to DOT1L inhibitor monotherapy. Phase Ib/II trials of pinometostat plus either standard chemotherapy or 5-azacytidine are ongoing in AML with MLL gene rearrangements (Table 3).
Myeloid differentiation induced by inhibition of BET proteins
Bromodomain and extra terminal (BET) family of proteins bind to acetyl-modified lysine residues of histone tails and activate transcription. A screen of RNA interference in a mouse AML model expressing the MLL-AF9 fusion and oncogenic NRAS identified BRD4, a BET family member, as indispensable for disease progression.85Genetic and pharmacological inactivation (JQ1 and I-BET151) of BRD4 led to downregulation of MYC, BCL2 and CDK6 in AML blasts, inhibited growth of MLL-rearranged AML cell lines and induced differentiation of primary leukemic samples and murine hematopoietic cells transformed with MLL fusions.85-87 Another BET bromodomain inhibitor, AZD5153, which ligates two bromodomains of BRD4 simultaneously, has prominent anti-proliferative activity against AML cell lines in vitro and in xenograft models.88 In other preclinical studies, BRD4 inhibitors exhibited anti-leukemic effects in AML driven by mutations of either IDH2, NPM1 or FLT3-ITD.89-91 Several BET inhibitors are currently under clinical investigation (Table 3); however, emerging results from these early phase trials are disappointing. In a phase I trial of OTX015 (MK-8628), this BET inhibitor elicited a clinical response in only five of 36 AML patients, with the response lasting 2–5 months.92 The clinical response to mivebresib (ABBV-075) was similarly inadequate and frequently associated with adverse effects including cytopenia.93 A number of trials of BET inhibitors have been terminated because of a combination of issues including low response rates, dose-limiting toxicities and inter-patient variability in pharmacokinetic properties (Table 3).
Improved drug design and combination strategies might establish the therapeutic utility of BET inhibitors. For instance, hetero-bifunctional compounds, BET-PROTAC (proteolysis-targeting chimera, ARV-825 and ARV-771), in which a BET inhibitor (OTX015/JQ1) is linked to a ligand for an E3 ubiquitin ligase (either cereblon or von Hippel– Lindau),94,95 have exhibited high potency in attenuating MYC and inducing apoptosis of AML cells.96 Moreover, concomitant inhibition of both BRD4 and DOT1L had significant synergistic activity against MLL-rearranged leukemia cell lines, primary human AML cells and murine leukemia models.97 Clearly, additional studies are needed to establish the clinical efficacy of drug combinations involving BET inhibitors.
Histone deacetylase inhibitors
Recruitment of HDAC is a major pathogenic event in AML subtypes driven by PML-RARA, inv(16) (CBFAMYH11) and RUNX1-RUNX1T1 chimeric proteins, indicating that inhibiting the activity of HDAC might be therapeutic. In preclinical studies, a combination of a HDAC inhibitor (trichostatin A) with ATRA relieved the differentiation block in ATRA-resistant APL cells. Panobinostat, another HDAC inhibitor, caused proteosomal degradation of the RUNX1-RUNX1T1 oncoprotein, triggering myeloid differentiation of leukemic cells in a murine model of human t(8;21) AML.98 Although several classes of HDAC inhibitors showed promise in preclinical models, their clinical efficacy as monotherapy was negligible in early phase clinical trials.99-102 Combinations of HDAC inhibitors with hypomethylating agents, chemotherapeutic agents or immunotherapy and targeted therapies are currently in different stages of clinical testing. Despite evidence of synergism between HDAC inhibitors and hypomethylating agents in preclinical and early clinical studies, large multi-arm clinical studies showed increased toxicity and decreased OS in patients treated with a HDAC inhibitor plus 5-azacytidine compared with 5-azacytidine alone.103-105 Collectively, the data suggest that HDAC inhibitors have limited clinical benefit, illustrating the potential problem of off-target effects arising from a lack of specificity of this approach.
Differentiation therapies in early clinical development
Differentiation of acute myeloid leukemia blasts using Aurora kinase inhibitors
Aurora kinases are serine/threonine kinases that regulate chromosomal alignment and segregation during mitosis and meiosis. Expression of Aurora kinase A and B is higher in leukemic blasts than in normal CD34+ cells.106 Inhibition of Aurora kinase A in acute megakaryocytic leukemia (AMKL) increases polyploidization of blasts and induces their differentiation.107 Furthermore, these inhibitors significantly prolonged survival of mice in an AMKL model, as well as mice engrafted with primary human AMKL cells.107,108 Alisertib, an Aurora kinase A inhibitor, is currently under clinical evaluation for use in the treatment of AMKL (NCT02530619). Several trials of either specific or dual inhibitors of Aurora kinase A and B showed moderate efficacy for treating other types of AML. In a phase I study, a combination of alisertib and conventional induction therapy (cytarabine and idarubicin) resulted in an 86% remission rate in newly diagnosed AML patients (NCT01779843),109 suggesting enhanced activity of this drug combination. Thus, Aurora kinase inhibitors may hold promise in AML therapy.
Restoration of TET activity with vitamin C promotes differentiation
TET proteins are dioxygenase enzymes that catalyze oxidation of 5-methylcytosine to 5-hydroxymethylcytosine, leading to DNA demethylation. The TET2 gene is frequently mutated in AML and other hematological malignancies, as well as in clonal hematopoiesis of indeterminate potential. 110 Stimulation of the remaining wild-type allele of TET2 is a plausible therapeutic approach.
In a murine model of reversible silencing of TET2, reexpression of Tet2 in hematopoietic cells primed the cells towards myeloid differentiation and promoted cell death.111 Vitamin C is a co-factor that activates TET proteins; and its depletion impairs the function of TET2 and accelerates tumorigenesis in a murine model of AML.112 Importantly, vitamin C treatment mimics pharmacological restoration of TET2 activity as evidenced by increased 5-hydroxymethylcytosine levels in AML cells and Tet2-deficient mice.111 In AML with biallelic TET2mutations or copy number neutral loss of heterozygosity of the TET2 locus, vitamin C might still enhance 5-hydroxymethylcytosine levels by potentiating TET3 activity, which can potentially compensate sufficiently for lack of TET2.111 Serum ascorbic acid (vitamin C) levels are significantly reduced in patients with diverse hematologic malignancies,113,114 and high doses of oral vitamin C might improve their outcome. The clinical efficacy of vitamin C combined with 5-azacytidine in patients with AML or myelodysplastic syndrome with or without TET2 mutations is currently being investigated (Table 3). Conceivably, dietary supplements of vitamin C may also help to augment TET2 activity and impede clonal hematopoietic progression in individuals with clonal hematopoiesis of indeterminate potential, especially those harboring mutant TET2.
Inhibition of DHODH relieves the block in myeloid differentiation in acute myeloid leukemia
HOXA9 is suppressed during myeloid differentiation, but its upregulation occurs in a large proportion of AML driven by different oncogenic events. In a murine model of inducible Hoxa9 expression, inhibition of dihydroorotate dehydrogenase (DHODH), a key enzyme in uridine synthesis that catalyzes conversion of dihydroorotate to orotate, induced terminal differentiation of leukemic cells.115 In an independent CRISPR/Cas9 screen of AML cell lines, loss of DHODH also decreased growth of AML cells.116 This suggests that targeting the de novo pyrimidine synthesis pathway may induce AML differentiation.
DHODH is neither mutated nor overexpressed in cancers; but cancer cells that are metabolically reprogrammed may have an increased dependency on de novo pyrimidine production,117 thus creating a potential therapeutic window. Earlier attempts to target DHODH with inhibitors (e.g., teriflunomide, brequinar, and leflunomide) in several cancers were unsuccessful because of either low potency or off-target effects.118 Subsequently, more potent and selective DHODH inhibitors (ASLAN003, BAY2402234 and PTC299) (Table 4) have been developed, which show antileukemic activity in various preclinical models;117,119-121 and are in early phase clinical trials.
The mechanism of action of DHODH inhibitors is unclear; but these drugs appear to have potential therapeutic value for the treatment of AML. However, by analogy with ATRA and the differentiating agents discussed above, it is unlikely that monotherapy will achieve durable responses.
Potential new targets for acute myeloid leukemia differentiation therapy
Recent studies have brought to light previously uncharacterized modulators of myeloid differentiation which can be targeted to overcome the differentiation block in AML. Pharmacological agents targeting these candidate modulators need to be developed to explore their clinical utility.
The CAF1 complex as a novel target for differentiation therapy of acute myeloid leukemia
CHAF1B is a subunit of the chromatin assembly factor 1 complex (CAF1) that facilitates assembly of H3-H4 tetramers at replication forks during the S phase. High CHAF1B levels are observed in leukemia and are associated with a poor prognosis.122 Overexpression of CHAF1B enhances the leukemic potential of the MLL-AF9 oncoprotein, and its inhibition promotes differentiation of leukemic cells.122 CHAF1B protein occupies discrete genomic loci and interferes with the CEBPA-mediated differentiation of leukemic cells;122 and is a potential therapeutic target.
Inhibiting transcriptional repressors to re-activate the myeloid differentiation program
A common feature of AML driven by different oncogenic events is increased recruitment of transcriptional co-repressors, which affects transcription of differentiation-promoting genes. Two co-repressors (SMARCA5 and CHD4) are enriched in the PU.1/RUNX1/CEBPA master transcription factor hub specifically in AML cells.123 An inhibitor of SMARCA5/CHD4 suppresses growth of AML cell lines via their terminal differentiation while not affecting growth of normal hematopoietic progenitors.123
Cell cycle regulators as therapeutic targets in acute myeloid leukemia
CDK6 is required for the growth and maintenance of an immature state of MLL-rearranged AML cells, and its suppression (by PD-0332991) induced myeloid differentiation in human and murine AML cells expressing the MLL fusion.124 Another cell cycle regulator, CDK1 phosphorylates CEBPA, thereby inhibiting its differentiation-inducing activity. In preclinical studies, pharmacological and genetic inhibition of CDK1 relieved the differentiation block in AML cells harboring mutations of FLT3.125 Inhibition of CDC25 using IRC-083864 can also overcome the differentiation block in FLT3-ITD AML cells..126 Overall, cell cycle regulators may be potential therapeutic targets in AML.
Combination therapies using differentiation-inducing agents
Combinatorial therapeutic approaches may be needed to increase efficacy and reduce development of resistance in AML. In APL, ATRA is effective in achieving remission by inducing terminal differentiation, but does not eradicate the leukemic clone; however, high cure rates are attained when ATRA is combined with arsenic or anthracycline. It is postulated that ATRA differentiation therapy in APL is unable to eliminate the leukemic stem cell, and this may also be relevant to differentiation therapy of AML more widely. In fact, a recent study revealed that mature APL cells become leukemogenic upon termination of ATRA treatment, suggesting that withdrawal of differentiation therapy can lead to reacquisition of clonogenic and leukemogenic properties through de-differentiation.127 Hence, combination regimens involving newly approved differentiation therapies (mutant IDH1/2 and FLT3 inhibitors) should be optimized for efficient clearing of the leukemic clones. Similarly, rational combination strategies might enhance the clinical utility of epigenetic inhibitors that have been largely ineffective as single agents.
Since 2017, four drugs (inhibitors of mutant IDH1/2 and FLT3) that induce differentiation of AML cells have been approved by the FDA. These novel therapeutic agents mark significant strides forward in differentiation therapy of AML. However, for other differentiation-inducing agents (e.g., inhibitors of HDAC, BET proteins, DOT1L), which showed promise in preclinical studies, early reports from clinical trials have not been encouraging. This highlights the limitations of preclinical efficacy models usually performed in immunocompromised mice lacking the immune component, as well as species-specific differences in drug pharmacokinetics and metabolism. Animal models are also limited in their ability to adequately replicate the molecular heterogeneity of AML. In addition, there is a pressing need to identify molecular subgroups which might be responsive to the new agents, as illustrated by the success of the RATIFY trial in assessing the benefit of midostaurin in FLT3-mutant AML. Another concern is that the new drugs may have been tested on limited cohorts of patients. For example, DOT1L inhibitors have been clinically evaluated in AML patients with rearranged MLL, but their differentiation-promoting activity has also been demonstrated in DNMT3Amutant AML cells in preclinical studies,128,129 suggesting that investigation of DOT1L inhibitors could be expanded to other cohorts of patients. In addition, initial trials usually involve patients with relapsed/refractory disease which can be biologically and clinically distinct from newly diagnosed AML. Overall, this illustrates that numerous difficulties need to be overcome for translation of preclinical candidates into clinically useful differentiation therapy. APL is arguably the least molecularly complex type of AML, which may be relevant to the early success of differentiation therapy in APL.
In summary, new insights into disease pathogenesis acquired from mutational and gene expression analyses have directed AML differentiation therapy to several novel targets. For many targets, pre-clinical potential has not translated into clinical success; nonetheless, additional promising targets (DHODH, Aurora kinases) have emerged and are being actively explored. Overall, we are in an exciting era of new therapeutic targets and drugs not imagined 10 years ago.
- Received June 10, 2020
- Accepted September 15, 2020
No Conflicts of interest to disclose
VM performed literature search and wrote the review, HPK conceived and wrote the manuscript.
- Dombret H, Gardin C.. An update of current treatments for adult acute myeloid leukemia. Blood. 2016; 127(1):53-61. https://doi.org/10.1182/blood-2015-08-604520PubMedPubMed CentralGoogle Scholar
- Cicconi L, Lo-Coco F.. Current management of newly diagnosed acute promyelocytic leukemia. Ann Oncol. 2016; 27(8):1474-1481. https://doi.org/10.1093/annonc/mdw171PubMedGoogle Scholar
- Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A. 1980; 77(5):2936-2940. https://doi.org/10.1073/pnas.77.5.2936PubMedPubMed CentralGoogle Scholar
- Drach J, Lopez-Berestein G, McQueen T, Andreeff M, Mehta K.. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res. 1993; 53(9):2100-2104. Google Scholar
- Schlenk RF, Frohling S, Hartmann F. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia. 2004; 18(11):1798-1803. https://doi.org/10.1038/sj.leu.2403528PubMedGoogle Scholar
- Schlenk RF, Döhner K, Krauter Jr. Alltrans retinoic acid improves outcome in younger adult patients with nucleophosmin- 1 mutated acute myeloid leukemia – results of the AMLSG 07-04 randomized treatment trial. Blood. 2011; 118(21):80. https://doi.org/10.1182/blood.V22.214.171.124PubMedGoogle Scholar
- Coombs CC, Tallman MS, Levine RL. Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol. 2016; 13(5):305-318. https://doi.org/10.1038/nrclinonc.2015.210PubMedPubMed CentralGoogle Scholar
- Petrie K, Zelent A, Waxman S.. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol. 2009; 16(2):84-91. https://doi.org/10.1097/MOH.0b013e3283257aeePubMedGoogle Scholar
- Burnett AK, Hills RK, Green C. The impact on outcome of the addition of alltrans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood. 2010; 115(5):948-956. https://doi.org/10.1182/blood-2009-08-236588PubMedGoogle Scholar
- Estey EH, Thall PF, Pierce S. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- alltrans retinoic acid +/- granulocyte colonystimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999; 93(8):2478-2484. https://doi.org/10.1182/blood.V93.8.2478PubMedGoogle Scholar
- Belhabri A, Thomas X, Wattel E. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. Hematol J. 2002; 3(1):49-55. https://doi.org/10.1038/sj.thj.6200141PubMedGoogle Scholar
- Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK, Group NHOCS. Fludarabine and cytosine are less effective than standard ADE chemotherapy in highrisk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006; 107(12):4614-4622. https://doi.org/10.1182/blood-2005-10-4202PubMedGoogle Scholar
- de The H.. Differentiation therapy revisited. Nat Rev Cancer. 2018; 18(2):117-127. https://doi.org/10.1038/nrc.2017.103PubMedGoogle Scholar
- Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood. 1983; 62(4):709-721. https://doi.org/10.1182/blood.V62.4.709.709PubMedGoogle Scholar
- Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009; 113(16):3655-3665. https://doi.org/10.1182/blood-2009-01-198911PubMedPubMed CentralGoogle Scholar
- Sachs L. The control of hematopoiesis and leukemia: from basic biology to the clinic. Proc Natl Acad Sci U S A. 1996; 93(10):4742-4749. https://doi.org/10.1073/pnas.93.10.4742PubMedPubMed CentralGoogle Scholar
- Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R.. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017; 31(2):272-281. https://doi.org/10.1038/leu.2016.275PubMedPubMed CentralGoogle Scholar
- Ward PS, Patel J, Wise DR. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-234. https://doi.org/10.1016/j.ccr.2010.01.020PubMedPubMed CentralGoogle Scholar
- Figueroa ME, Abdel-Wahab O, Lu C. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-567. https://doi.org/10.1016/j.ccr.2010.11.015PubMedPubMed CentralGoogle Scholar
- Lu C, Ward PS, Kapoor GS. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012; 483(7390):474-478. https://doi.org/10.1038/nature10860PubMedPubMed CentralGoogle Scholar
- Xu W, Yang H, Liu Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011; 19(1):17-30. https://doi.org/10.1016/j.ccr.2010.12.014PubMedPubMed CentralGoogle Scholar
- Popovici-Muller J, Lemieux RM, Artin E. Discovery of AG-120 (ivosidenib): a firstin- class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018; 9(4):300-305. https://doi.org/10.1021/acsmedchemlett.7b00421PubMedPubMed CentralGoogle Scholar
- DiNardo CD, Stein EM, de Botton S. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018; 378(25):2386-2398. https://doi.org/10.1056/NEJMoa1716984PubMedGoogle Scholar
- Roboz GJ, DiNardo CD, Stein EM. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1- mutant acute myeloid leukemia. Blood. 2020; 135(7):463-471. https://doi.org/10.1182/blood.2019002140PubMedPubMed CentralGoogle Scholar
- Dinardo CD, Stein AS, Stein EM. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). J Clin Oncol. 2019; 37(15_suppl):7011. https://doi.org/10.1200/JCO.2019.37.15_suppl.7011Google Scholar
- Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol. 2018; 14(10):979-993. https://doi.org/10.2217/fon-2017-0523PubMedGoogle Scholar
- Wang F, Travins J, DeLaBarre B. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013; 340(6132):622-626. https://doi.org/10.1126/science.1234769PubMedGoogle Scholar
- Yen K, Travins J, Wang F. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017; 7(5):478-493. https://doi.org/10.1158/2159-8290.CD-16-1034PubMedGoogle Scholar
- Stein EM, DiNardo CD, Pollyea DA. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017; 130(6):722-731. https://doi.org/10.1182/blood-2017-04-779405PubMedPubMed CentralGoogle Scholar
- Pollyea DA, Tallman MS, de Botton S. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019; 33(11):2575-2584. https://doi.org/10.1038/s41375-019-0472-2PubMedGoogle Scholar
- Amatangelo MD, Quek L, Shih A. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017; 130(6):732-741. https://doi.org/10.1182/blood-2017-04-779447PubMedPubMed CentralGoogle Scholar
- Stein EM, DiNardo CD, Fathi AT. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019; 133(7):676-687. https://doi.org/10.1182/blood-2018-08-869008PubMedPubMed CentralGoogle Scholar
- DiNardo CD, Schuh AC, Stein EM. Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: interim phase II results from an ongoing, randomized study. Blood. 2019; 134(Suppl_1):643. https://doi.org/10.1182/blood-2019-130362PubMedGoogle Scholar
- Stein EM, DiNardo CD, Mims AS. Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: initial results from a phase 1 trial. Blood. 2017; 130(Supplement_1):726. Google Scholar
- Intlekofer AM, Shih AH, Wang B. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018; 559(7712):125-129. https://doi.org/10.1038/s41586-018-0251-7PubMedPubMed CentralGoogle Scholar
- Quek L, David MD, Kennedy A. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018; 24(8):1167-1177. https://doi.org/10.1038/s41591-018-0115-6PubMedPubMed CentralGoogle Scholar
- Choe S, Wang H, DiNardo CD. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1- mutant relapsed or refractory AML. Blood Adv. 2020; 4(9):1894-1905. https://doi.org/10.1182/bloodadvances.2020001503PubMedPubMed CentralGoogle Scholar
- Montesinos P, Bergua JM, Vellenga E. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009; 113(4):775-783. https://doi.org/10.1182/blood-2008-07-168617PubMedGoogle Scholar
- Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012; 120(10):1993-2002. https://doi.org/10.1182/blood-2012-04-424440PubMedGoogle Scholar
- Norsworthy KJ, Mulkey F, Scott EC. Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis. Clin Cancer Res. 2020; 26(16):4280-4288. https://doi.org/10.1158/1078-0432.CCR-20-0834PubMedPubMed CentralGoogle Scholar
- Fathi AT, DiNardo CD, Kline I. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol. 2018; 4(8):1106-1110. https://doi.org/10.1001/jamaoncol.2017.4695PubMedPubMed CentralGoogle Scholar
- Tallman MS, Andersen JW, Schiffer CA. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000; 95(1):90-95. Google Scholar
- Tallman MS, Andersen JW, Schiffer CA. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997; 337(15):1021-1028. https://doi.org/10.1056/NEJM199710093371501PubMedGoogle Scholar
- Radomska HS, Basseres DS, Zheng R. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med. 2006; 203(2):371-381. https://doi.org/10.1084/jem.20052242PubMedPubMed CentralGoogle Scholar
- Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen YB. FLT3 inhibitor-induced neutrophilic dermatosis. Blood. 2013; 122(2):239-242. https://doi.org/10.1182/blood-2013-01-478172PubMedGoogle Scholar
- Man CH, Fung TK, Ho C. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012; 119(22):5133-5143. https://doi.org/10.1182/blood-2011-06-363960PubMedGoogle Scholar
- Varadarajan N, Boni A, Elder DE. FLT3 inhibitor-associated neutrophilic dermatoses. JAMA Dermatol. 2016; 152(4):480-482. https://doi.org/10.1001/jamadermatol.2015.6121PubMedGoogle Scholar
- Mori M, Kaneko N, Ueno Y. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017; 35(5):556-565. https://doi.org/10.1007/s10637-017-0470-zPubMedPubMed CentralGoogle Scholar
- Perl AE, Altman JK, Cortes J. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017; 18(8):1061-1075. https://doi.org/10.1016/S1470-2045(17)30416-3PubMedPubMed CentralGoogle Scholar
- McMahon CM, Canaani J, Rea B. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 2019; 3(10):1581-1585. https://doi.org/10.1182/bloodadvances.2018029496PubMedPubMed CentralGoogle Scholar
- Perl AE, Martinelli G, Cortes JE. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase III ADMIRAL trial. Cancer Res. 2019; 79:13. https://doi.org/10.1097/01.HS9.0000561784.84381.11Google Scholar
- Short NJ, Kantarjian H, Ravandi F, Daver N.. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol. 2019; 10:2040620719827310. https://doi.org/10.1177/2040620719827310PubMedPubMed CentralGoogle Scholar
- Cortes JE, Khaled S, Martinelli G. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019; 20(7):984-997. https://doi.org/10.1016/S1470-2045(19)30150-0Google Scholar
- Sexauer A, Perl A, Yang X. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012; 120(20):4205-4214. https://doi.org/10.1182/blood-2012-01-402545PubMedPubMed CentralGoogle Scholar
- Swaminathan M, Kantarjian HM, Daver N. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood. 2017; 130(Supplement 1):723. Google Scholar
- Fischer T, Stone RM, Deangelo DJ. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010; 28(28):4339-4345. https://doi.org/10.1200/JCO.2010.28.9678PubMedPubMed CentralGoogle Scholar
- Stone RM, Fischer T, Paquette R. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012; 26(9):2061-2068. https://doi.org/10.1038/leu.2012.115PubMedPubMed CentralGoogle Scholar
- Stone RM, Mandrekar SJ, Sanford BL. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017; 377(5):454-464. https://doi.org/10.1056/NEJMoa1614359PubMedPubMed CentralGoogle Scholar
- Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2):299-312. https://doi.org/10.1038/s41375-018-0357-9PubMedPubMed CentralGoogle Scholar
- Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2017; 16(6):991-1001. https://doi.org/10.1158/1535-7163.MCT-16-0876PubMedPubMed CentralGoogle Scholar
- Ma J, Zhao S, Qiao X. Inhibition of Bcl- 2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia. Clin Cancer Res. 2019; 25(22):6815-6826. https://doi.org/10.1158/1078-0432.CCR-19-0832PubMedPubMed CentralGoogle Scholar
- Zhang H, Savage S, Schultz AR. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019; 10(1):244. https://doi.org/10.1038/s41467-018-08263-xPubMedPubMed CentralGoogle Scholar
- McMahon CM, Ferng T, Canaani J. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019; 9(8):1050-1063. https://doi.org/10.1158/2159-8290.CD-18-1453PubMedGoogle Scholar
- Smith CC, Paguirigan A, Jeschke GR. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by singlecell analysis. Blood. 2017; 130(1):48-58. https://doi.org/10.1182/blood-2016-04-711820PubMedPubMed CentralGoogle Scholar
- Smith CC, Wang Q, Chin CS. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012; 485(7397):260-263. https://doi.org/10.1038/nature11016PubMedPubMed CentralGoogle Scholar
- Harris WJ, Huang X, Lynch JT. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012; 21(4):473-487. https://doi.org/10.1016/j.ccr.2012.03.014PubMedGoogle Scholar
- Schenk T, Chen WC, Gollner S. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012; 18(4):605-611. https://doi.org/10.1038/nm.2661PubMedPubMed CentralGoogle Scholar
- Cusan M, Cai SF, Mohammad HP. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPalpha-dependent enhancers in AML. Blood. 2018; 131(15):1730-1742. https://doi.org/10.1182/blood-2017-09-807024PubMedPubMed CentralGoogle Scholar
- McGrath JP, Williamson KE, Balasubramanian S. Pharmacological inhibition of the histone lysine demethylase KDM1A suppresses the growth of multiple acute myeloid leukemia subtypes. Cancer Res. 2016; 76(7):1975-1988. https://doi.org/10.1158/0008-5472.CAN-15-2333PubMedGoogle Scholar
- Maes T, Mascaro C, Tirapu I. ORY-. 1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia. Cancer Cell. 2018; 33(3):495-511. https://doi.org/10.1016/j.ccell.2018.02.002PubMedGoogle Scholar
- Somervaille TC, Salamero O, Montesinos P. Safety, phamacokinetics (PK), pharmacodynamics (PD) and preliminary activity in acute leukemia of Ory-1001, a first-in-class inhibitor of lysine-specific histone demethylase 1A (LSD1/KDM1A): initial results from a first-in-human phase 1 study. Blood. 2016; 128(22):4060. https://doi.org/10.1182/blood.V128.22.4060.4060PubMedGoogle Scholar
- Guenther MG, Lawton LN, Rozovskaia T. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008; 22(24):3403-3408. https://doi.org/10.1101/gad.1741408PubMedPubMed CentralGoogle Scholar
- Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 2005; 65(24):11367-11374. https://doi.org/10.1158/0008-5472.CAN-05-1041PubMedGoogle Scholar
- Nguyen AT, Taranova O, He J, Zhang Y.. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood. 2011; 117(25):6912-6922. https://doi.org/10.1182/blood-2011-02-334359PubMedPubMed CentralGoogle Scholar
- Bernt KM, Zhu N, Sinha AU. MLLrearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011; 20(1):66-78. https://doi.org/10.1016/j.ccr.2011.06.010PubMedPubMed CentralGoogle Scholar
- Deshpande AJ, Chen L, Fazio M. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 2013; 121(13):2533-2541. https://doi.org/10.1182/blood-2012-11-465120PubMedPubMed CentralGoogle Scholar
- Daigle SR, Olhava EJ, Therkelsen CA. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011; 20(1):53-65. https://doi.org/10.1016/j.ccr.2011.06.009PubMedPubMed CentralGoogle Scholar
- Chen L, Deshpande AJ, Banka D. Abrogation of MLL-AF10 and CALM-AF10- mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013; 27(4):813-822. https://doi.org/10.1038/leu.2012.327PubMedPubMed CentralGoogle Scholar
- Daigle SR, Olhava EJ, Therkelsen CA. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013; 122(6):1017-1025. https://doi.org/10.1182/blood-2013-04-497644PubMedPubMed CentralGoogle Scholar
- Stein EM, Garcia-Manero G, Rizzieri DA. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018; 131(24):2661-2669. https://doi.org/10.1182/blood-2017-12-818948PubMedPubMed CentralGoogle Scholar
- Klaus CR, Iwanowicz D, Johnston D. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther. 2014; 350(3):646-656. https://doi.org/10.1124/jpet.114.214577PubMedGoogle Scholar
- Kuhn MW, Song E, Feng Z. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 2016; 6(10):1166-1181. https://doi.org/10.1158/2159-8290.CD-16-0237PubMedPubMed CentralGoogle Scholar
- Dafflon C, Craig VJ, Mereau H. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Leukemia. 2017; 31(6):1269-1277. https://doi.org/10.1038/leu.2016.327PubMedGoogle Scholar
- Feng Z, Yao Y, Zhou C. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol. 2016; 9:24. https://doi.org/10.1186/s13045-016-0252-7PubMedPubMed CentralGoogle Scholar
- Zuber J, Shi J, Wang E. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011; 478(7370):524-528. https://doi.org/10.1038/nature10334PubMedPubMed CentralGoogle Scholar
- Dawson MA, Prinjha RK, Dittmann A. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011; 478(7370):529-533. https://doi.org/10.1038/nature10509PubMedPubMed CentralGoogle Scholar
- Mertz JA, Conery AR, Bryant BM. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011; 108(40):16669-16674. https://doi.org/10.1073/pnas.1108190108PubMedPubMed CentralGoogle Scholar
- Rhyasen GW, Hattersley MM, Yao Y. AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies. Mol Cancer Ther. 2016; 15(11):2563-2574. https://doi.org/10.1158/1535-7163.MCT-16-0141PubMedGoogle Scholar
- Fiskus W, Sharma S, Qi J. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther. 2014; 13(10):2315-2327. https://doi.org/10.1158/1535-7163.MCT-14-0258PubMedPubMed CentralGoogle Scholar
- Chen C, Liu Y, Lu C. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 2013; 27(18):1974-1985. https://doi.org/10.1101/gad.226613.113PubMedPubMed CentralGoogle Scholar
- Dawson MA, Gudgin EJ, Horton SJ. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia. 2014; 28(2):311-320. https://doi.org/10.1038/leu.2013.338PubMedPubMed CentralGoogle Scholar
- Berthon C, Raffoux E, Thomas X. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016; 3(4):e186-195. https://doi.org/10.1016/S2352-3026(15)00247-1Google Scholar
- Odenike O, Wolff JE, Borthakur G. Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2019; 37(15_suppl):7030. https://doi.org/10.1200/JCO.2019.37.15_suppl.7030Google Scholar
- Lu J, Qian Y, Altieri M. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol. 2015; 22(6):755-763. https://doi.org/10.1016/j.chembiol.2015.05.009PubMedPubMed CentralGoogle Scholar
- Raina K, Lu J, Qian Y. PROTACinduced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016; 113(26):7124-7129. https://doi.org/10.1073/pnas.1521738113PubMedPubMed CentralGoogle Scholar
- Saenz DT, Fiskus W, Qian Y. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017; 31(9):1951-1961. https://doi.org/10.1038/leu.2016.393PubMedPubMed CentralGoogle Scholar
- Gilan O, Lam EY, Becher I. Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat Struct Mol Biol. 2016; 23(7):673-681. https://doi.org/10.1038/nsmb.3249PubMedGoogle Scholar
- Bots M, Verbrugge I, Martin BP. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood. 2014; 123(9):1341-1352. https://doi.org/10.1182/blood-2013-03-488114PubMedPubMed CentralGoogle Scholar
- Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 2011; 25(2):226-235. https://doi.org/10.1038/leu.2010.276PubMedGoogle Scholar
- Schaefer EW, Loaiza-Bonilla A, Juckett M. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009; 94(10):1375-1382. https://doi.org/10.3324/haematol.2009.009217PubMedPubMed CentralGoogle Scholar
- Kirschbaum MH, Foon KA, Frankel P. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium study. Leuk Lymphoma. 2014; 55(10):2301-2304. https://doi.org/10.3109/10428194.2013.877134PubMedPubMed CentralGoogle Scholar
- Schlenk RF, Krauter J, Raffoux E. Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials. Haematologica. 2018; 103(1):e25-e28. https://doi.org/10.3324/haematol.2017.172411PubMedPubMed CentralGoogle Scholar
- Bewersdorf JP, Shallis R, Stahl M, Zeidan AM. Epigenetic therapy combinations in acute myeloid leukemia: what are the options?. Ther Adv Hematol. 2019; 10:2040620718816698. https://doi.org/10.1177/2040620718816698PubMedPubMed CentralGoogle Scholar
- Prebet T, Sun Z, Ketterling RP. Azacitidine with or without entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol. 2016; 172(3):384-391. https://doi.org/10.1111/bjh.13832PubMedPubMed CentralGoogle Scholar
- Garcia-Manero G, Sekeres MA, Egyed M. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts. Leukemia. 2017; 31(12):2799-2806. https://doi.org/10.1038/leu.2017.159PubMedPubMed CentralGoogle Scholar
- Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Oncogene. 2015; 34(5):537-545. https://doi.org/10.1038/onc.2014.14PubMedPubMed CentralGoogle Scholar
- Wen Q, Goldenson B, Silver SJ. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell. 2012; 150(3):575-589. https://doi.org/10.1016/j.cell.2012.06.032PubMedPubMed CentralGoogle Scholar
- Thiollier C, Lopez CK, Gerby B. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med. 2012; 209(11):2017-2031. https://doi.org/10.1084/jem.20121343PubMedPubMed CentralGoogle Scholar
- Fathi AT, Wander SA, Blonquist TM. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017; 102(4):719-727. https://doi.org/10.3324/haematol.2016.158394PubMedPubMed CentralGoogle Scholar
- Bowman RL, Levine RL. TET2 in normal and malignant hematopoiesis. Cold Spring Harb Perspect Med. 2017; 7(8):a026518. https://doi.org/10.1101/cshperspect.a026518PubMedPubMed CentralGoogle Scholar
- Cimmino L, Dolgalev I, Wang Y. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017; 170(6):1079-1095. https://doi.org/10.1016/j.cell.2017.07.032PubMedPubMed CentralGoogle Scholar
- Agathocleous M, Meacham CE, Burgess RJ. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature. 2017; 549(7673):476-481. https://doi.org/10.1038/nature23876PubMedPubMed CentralGoogle Scholar
- Liu M, Ohtani H, Zhou W. Vitamin C increases viral mimicry induced by 5-aza-2'- deoxycytidine. Proc Natl Acad Sci U S A. 2016; 113(37):10238-10244. https://doi.org/10.1073/pnas.1612262113PubMedPubMed CentralGoogle Scholar
- Waldo AL, Zipf RE. Ascorbic acid level in leukemic patients. Cancer. 1955; 8(1):187-190. https://doi.org/10.1002/1097-0142(1955)8:1<187::AID-CNCR2820080126>3.0.CO;2-SGoogle Scholar
- Sykes DB, Kfoury YS, Mercier FE. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016; 167(1):171-186. https://doi.org/10.1016/j.cell.2016.08.057PubMedPubMed CentralGoogle Scholar
- Tzelepis K, Koike-Yusa H, De Braekeleer E. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 2016; 17(4):1193-1205. https://doi.org/10.1016/j.celrep.2016.09.079PubMedPubMed CentralGoogle Scholar
- Sykes DB. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia. Expert Opin Ther Targets. 2018; 22(11):893-898. https://doi.org/10.1080/14728222.2018.1536748PubMedPubMed CentralGoogle Scholar
- Madak JT, Bankhead A, Cuthbertson CR, Showalter HD, Neamati N. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharmacol Ther. 2019; 195:111-131. https://doi.org/10.1016/j.pharmthera.2018.10.012PubMedGoogle Scholar
- Cao L, Weetall M, Trotta C. Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties. Mol Cancer Ther. 2019; 18(1):3-16. https://doi.org/10.1158/1535-7163.MCT-18-0863PubMedPubMed CentralGoogle Scholar
- Zhou J, Quah JY, Chooi JY. ASLAN003, a novel and potent dihydroorotate dehydrogenase (DHODH) inhibitor, induces differentiation of acute myeloid leukemia. Blood. 2018; 132(Suppl_1):4047. https://doi.org/10.1182/blood-2018-99-114392PubMedGoogle Scholar
- Christian S, Merz C, Evans L. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. 2019; 33(10):2403-2415. https://doi.org/10.1038/s41375-019-0461-5PubMedGoogle Scholar
- Volk A, Liang K, Suraneni P. A CHAF1B-dependent molecular switch in hematopoiesis and leukemia pathogenesis. Cancer Cell. 2018; 34(5):707-723. https://doi.org/10.1016/j.ccell.2018.10.004PubMedPubMed CentralGoogle Scholar
- Kishtagari A, Ng KP, Jarman C. A firstin- class inhibitor of ISWI-mediated (ATPDependent) transcription repression releases terminal-differentiation in AML cells while sparing normal hematopoiesis. Blood. 2018; 132(Suppl_1):216. https://doi.org/10.1182/blood-2018-99-119311PubMedGoogle Scholar
- Placke T, Faber K, Nonami A. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014; 124(1):13-23. https://doi.org/10.1182/blood-2014-02-558114PubMedPubMed CentralGoogle Scholar
- Radomska HS, Alberich-Jorda M, Will B, Gonzalez D, Delwel R, Tenen DG. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPalpha. J Clin Invest. 2012; 122(8):2955-2966. https://doi.org/10.1172/JCI43354PubMedPubMed CentralGoogle Scholar
- Bertoli S, Boutzen H, David L. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. Oncotarget. 2015; 6(35):38061-38078. https://doi.org/10.18632/oncotarget.5706PubMedPubMed CentralGoogle Scholar
- McKenzie MD, Ghisi M, Oxley EP. Interconversion between tumorigenic and differentiated states in acute myeloid leukemia. Cell Stem Cell. 2019; 25(2):258-272. https://doi.org/10.1016/j.stem.2019.07.001PubMedGoogle Scholar
- Rau RE, Rodriguez BA, Luo M. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016; 128(7):971-981. https://doi.org/10.1182/blood-2015-11-684225PubMedPubMed CentralGoogle Scholar
- Lu R, Wang P, Parton T. Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development. Cancer Cell. 2016; 30(1):92-107. https://doi.org/10.1016/j.ccell.2016.05.008PubMedPubMed CentralGoogle Scholar
Figures & Tables
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.